Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B
May 10, 2019 08:00 ET | uniQure Inc.
~ Increases in FIX Activity Sustained at up to 57% of Normal, with Mean FIX of 47% of Normal at Six Months After Administration ~ ~ None of the Patients Received Factor Infusions or Reported...